Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1%

Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with re-spect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin. Copyright (C) 2012 S. Karger AG, Base

Classification Of Neurodegenerative Diseases From Extraction Of Salient Brain Patterns

Neurodegenerative diseases causes a wide variety of mental symptoms whose evolution is not directly related to the analysis made by radiologists on basis of images, who can hardly quantify systematic differences. This paper presents a new automatic (Based on software program) image analysis method that reveals different brain patterns associated to the presence of neurodegenerative diseases, finding systematic differences and therefore grading objectively any neurological disorder. An accurate solution can be provided by using Alzheimer's diseases based on saliency map characterization is carried out on database images. This paper gives automatic image analysis method and attempts an approach for classification of brain images to search for pathology and normality part of brain by extracting salient features of input brain image and the region of interest is identified using kernel k-means algorithm. A support vector machine (SVM) a supervised learning process is used for classification of AD, which is recognized on basis of blue color is normal brain part and red color is pathology related

Extraction of Feature From Satellite Images-using Pan Chromatic Sharpening

Satellite data has been successfully used in various application fields, as it provide a perfect view of a desired region. Satellite images of different resolutions are commercially available. . To obtain more precise and meaning full data from satellite image different preprocessing techniques are available. Panchromatic sharpening is one of the most used technique in remote sensing imaginary. This Sharpenedimage can be used in various application such as vegetation detection, water bodies detection, highways detection etc. and to extract important features from image data such as area calculation. This will make a description, implementation or understanding of the scene more informative and user friendly by machine

Study Of Topical Anti-Inflammatory Potency And Clinical Efficacy Of Formulations Of Mometasone And Betamethasone By Cutaneous Blood Flow Measurements In Psoriatic Patients Using Laser Doppler Velocimetry

Laser Doppier Velocimetry (LDV) was used to measure cutaneous blood flow (CBF) in psoriatic skin lesions to assess the effect of once daily application of Mometasone furoate (MF) in a base claimed to possess a â€reservoir†effect, as against Betamethasone-17-valarate (BV) in a conventional cream base, applied twice daily, for 4 weeks. Bilaterally symmetrical active lesions were studied in 10 psoriatics, at baseline and at the end of 2 and 4 weeks†treatment. The formulations were also evaluated for topical anti-inflammatory potency in terms of their ability to inhibit the Post-Ischaemic-Reactive-Hyperaemic-Response (PIRHR) induced on normal uninvolved skin treated under occlusion. The lesions were also assessed subjectively for clinical Psoriatic Hyperaemia Index (PHI = CBF on lesions/CBF on uninvolved skin: 8.42 + 1.74 & 10.13 + 1.70) correlating with high CPI (9 + 0.50 & 9.1 + 0.51). During treatment with MF or BV, the lesions resolved rapidly, with a concomitant decrease in PHI and CPI (Week 2 : PHI = 3.40 + 0.46 & 5.19 + 1.65, CPI = 4.15 + 0.86& 5.20 + 0.87 and Week 4 : PHI = 1.99 + 0.23 & 2.81 + 0.74 CPI = 2.00 + 0.50 & 2.88 + 0.72 respectively). The two formulations Inhibited PIRHR to same extent (auc/min: Control = 1871 + 399.22, MF = 536.11 + 153.34 & BV = 567.5 + 110.76), indicating equal potency. The results show that pharmaceutical factor such as vehicle can significantly influence the clinical efficacy of corticoids